On October 6, Allogene announced the initiation of the Phase II ALPHA2 trial of the investigational allogeneic CAR T therapy ALLO-501A for the treatment of
When it comes to cancer, everyone is very worried. The incidence and mortality of cancer worldwide are rising. According to statistics [1], the global cancer
While there is no cure for lupus erythematosus and existing treatments don’t work for many of the 1.5 million lupus erythematosus patients in the U.S.,
On August 1, 2022, base editing company Beam Therapeutics announced that its IND application for BEAM-201 was suspended by the FDA. The FDA will provide
Since the launch of the first CAR-T cell therapy in 2017, the era of cell therapy has officially begun, and good clinical results have been
